Targeted drug therapy shows promise against deadly form of lung cancerNovember 2nd, 2010 - 5:05 pm ICT by ANI
London, Nov 2 (ANI): Scientists say that a targeted therapy is showing great promise in patients with a deadly form of lung cancer.
The multicenter study is testing whether the drug crizotinib effectively slows, stops or reverses growth in advanced non-small cell lung cancer tumors by targeting a genetic mutation that causes uncontrolled tumor growth. Study participants all tested positive for a mutation in the anaplastic lymphoma kinase gene.
According to the findings, tumors disappeared or shrank in 57 percent of patients. Tumors ceased growing in another 33 percent. The response rate to the current standard of care for advanced non-small cell lung cancer is about 15 percent.
“For the majority of patients, the treatment right now is chemotherapy plus targeted therapy in those eligible,” said Dr. Ignatius Ou. “In the future, with the advance of personalized medicine, we hope to be able to identify specific genetic change in the lung cancer and treat patients with specific inhibitors that can improve survival rates and quality of life.”
The study includes data from 82 patients treated in Phase 1 of this study, sponsored by the pharmaceutical company Pfizer. The targeted genetic mutation is particularly prevalent among those who have never smoked. Study participants ranged in age from 25 to 78, with 76 percent of them nonsmokers.
Ou treated 15 patients in UC Irvine’s Phase 1 trial, most from Los Angeles, Orange and San Diego counties. One person came from Arizona each month for treatment and assessment. Ou is currently enrolling patients in Phase 2 and 3 trials for crizotinib. Interested candidates should contact the UCI clinical trials office at 714-456-6241.
Each year, about 1.5 million new cases of lung cancer are diagnosed globally. Nearly 75 percent of people with non-small cell lung cancer are diagnosed at an advanced stage, for which the five-year survival rate is only 6 percent.
Recent cancer research emphasizes targeting, or personalizing, treatment through molecular analysis of a tumor and the use of a specific drug to inhibit genetic expression. Conventional chemotherapy bombards a tumor with multiple drugs.
According to the National Cancer Institute, because targeted cancer therapies are more selective for cancer cells, they may harm fewer normal cells, reduce side effects and improve quality of life.
The study has been published in New England Journal of Medicine. (ANI)
- 'Smart' lung cancer drug shows promise - Oct 28, 2010
- New drug shows promise against certain lung cancers - Oct 29, 2010
- Gene mutations help leukemia drug fight squamous cell lung cancer - Apr 04, 2011
- TTF therapy, chemo combo 'increase survival for lung cancer patients' - Oct 11, 2010
- New drug shows dramatic results in reducing lung cancer tumours - Jun 23, 2010
- New treatment strategy effective for certain lung cancers - Mar 11, 2011
- Indian-origin scientist discovers cold virus that kills cancer - Oct 21, 2010
- New drug shows promise against ovarian and breast cancer - Aug 13, 2010
- New discovery shows promise against non-small cell lung cancer - Dec 04, 2010
- FDA approves personalized therapy for tough-to-treat colorectal cancer - Jul 26, 2012
- Indian-origin scientist's finding offers hope for advanced cancer patients - Apr 06, 2011
- Gene set shows which patients benefit from chemo after surgery - Sep 08, 2010
- Chemo-Vandetanib combo effective for lung cancer treatment: Study - Jun 06, 2010
- Targeted cancer drug more effective after first-line treatment - Feb 28, 2011
- New way of treating lung cancer soon - Oct 11, 2011
Tags: anaplastic lymphoma, cancer research, cancer tumors, cell lung cancer, five year survival, genetic change, genetic mutation, interested candidates, lung cancer, multicenter study, non small cell lung cancer, pharmaceutical company, response rate, san diego counties, small cell lung cancer, study participants, survival rate, survival rates, tumor growth, uc irvine